How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

287 results for

Baclofen Withdrawal

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Intrathecal baclofen in paroxysmal sympathetic hyperactivity: Impact on oral treatment Full Text available with Trip Pro

Intrathecal baclofen in paroxysmal sympathetic hyperactivity: Impact on oral treatment Intrathecal baclofen (ITB) is a commonly used treatment in severe spasticity. The main objective of this study was to assess the impact of ITB on reduction or withdrawal of oral drugs in patients with paroxysmal sympathetic hyperactivity (PSH) after severe traumatic brain injury.We retrospectively evaluated 20 patients with PSH due to severe traumatic brain injury who were treated with ITB in a primary care (...) and referral center of neurology. Rates of and time until complete withdrawal or possible reduction in oral baclofen and oral propranolol after ITB treatment were calculated. Moreover, vegetative parameters (heart rate and blood pressure) as well as hypertonic attacks were assessed.The median time of complete oral baclofen disposal was 5 ± 3.7 (CI 95% [2.9-7.1], range 0-14) days after ITB pump implantation in 20 of 20 patients, and the median time of complete oral propranolol disposal was 24 ± 62.97 (CI 95

2018 Brain and behavior

22. Pregnancy and Breastfeeding during Intrathecal Baclofen Therapy – A Case Study and Review Full Text available with Trip Pro

score was 8 at 1 min and 9 at 5 min, and birth-weight was 2,704 g. We measured the baclofen concentration in the patient's breast milk using high-performance liquid chromatography/tandem mass spectrometry. The level of baclofen in the breast milk was very low (0.617 ng/ml) and the predicted pharmacological effect on the infant was judged to be negligible. No withdrawal symptoms or muscle tone abnormalities were found after birth. Our findings indicate that ITB therapy could be considered for young (...) Pregnancy and Breastfeeding during Intrathecal Baclofen Therapy – A Case Study and Review We report the case of a young woman who received intrathecal baclofen therapy (ITB) and subsequently became pregnant and had a normal delivery. A 28-year-old woman with flexion myelopathy had anterior decompression with fusion at C4/5 and C5/6 levels. Clinical symptoms improved after surgery. However, when she was 29 years old, her symptoms steadily advanced to Modified Ashworth Scale 3 spasticity level

2018 NMC Case Report Journal

23. How to Manage Self-Poisoning With Baclofen in Alcohol Use Disorder? Current Updates Full Text available with Trip Pro

complications include prolonged QTc interval, degree heart block, premature atrial contractions, and supraventricular tachycardia, hypotension and bradycardia. In cases of intoxication, the elimination half-life of baclofen may last between 12 and 36 h post-overdose and renal failure is known to delay its clearance. Rarely measured in clinical practice, the toxic level of baclofen blood level ranges from 1.1 to 3.5 mg/l, and coma or fatal intoxication are observed from 6 to 9.6 mg/l. Baclofen withdrawal has (...) been observed but making the diagnosis of withdrawal in case of suspected self-poisoning is difficult as baclofen intoxication and baclofen withdrawal share many clinical signs. Admission to hospital to manage of suicide attempt with baclofen is mandatory and should not be limited to baclofen alone. It needs to include other aspects of the overall care of patients with alcohol disorders (psychological and psychosocial interventions, management of comorbid mental conditions and physical

2018 Frontiers in Psychiatry

24. Alcohol Withdrawal Management for Acute Care Inpatients

-based guidelines were identified; therefore, no summary of recommendations can be presented. Among the systematic reviews, various interventions for alcohol withdrawal syndrome (AWS) were assessed, including intravenous ethanol replacement, 5 unspecified prophylactic treatment, 1 benzodiazepines (BZD), 2-3,5 anticonvulsants, 2 baclofen, 3 magnesium, 4 gamma- hydroxybutyric acid (GHB), 5 clomethiazole, 5 phenobarbital, 5 clonidine, 5 and haloperidol. 5 Treatment benefits were shown for BZDs 2 (...) is unproven ? Optimal treatment for AWS yet to be determined ? Early and aggressive titration of unspecified medication as guided by symptoms is associated with improved outcomes Kattimani, 2013 2 BZD Best evidence for benefit in treating AWS Evidence supports guidance of initial treatment dosing by risk factors for complicated withdrawal followed by withdrawal severity Anticonvulsants Evidence second to BZD for treating AWS Liu, 2013 3 Baclofen ? One study reported that both treatments significantly

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

25. Cost-effectiveness analysis of baclofen and chlordiazepoxide in uncomplicated alcohol-withdrawal syndrome. Full Text available with Trip Pro

Cost-effectiveness analysis of baclofen and chlordiazepoxide in uncomplicated alcohol-withdrawal syndrome. Benzodiazepines (BZDs) are the first-line drugs in alcohol-withdrawal syndrome (AWS). Baclofen, a gamma-aminobutyric acidB (GABAB) agonist, controls withdrawal symptoms without causing significant adverse effects. The objective of this study was to compare the cost-effectiveness of baclofen and chlordiazepoxide in the management of uncomplicated AWS.This was a randomized, open label (...) , standard controlled, parallel group study of cost-effectiveness analysis (CEA) of baclofen and chlordiazepoxide in 60 participants with uncomplicated AWS. Clinical efficacy was measured by the Clinical Institute Withdrawal Assessment for alcohol (CIWA-Ar) scores. Lorazepam was used as supplement medication if withdrawal symptoms could not be controlled effectively by the study drugs alone. Both direct and indirect medical costs were considered and the CEA was analyzed in both patient's perspective

2014 Indian journal of pharmacology Controlled trial quality: uncertain

26. Preventing Alcohol Withdrawal Syndrome With Oral Baclofen

Preventing Alcohol Withdrawal Syndrome With Oral Baclofen Preventing Alcohol Withdrawal Syndrome With Oral Baclofen - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Preventing Alcohol Withdrawal Syndrome (...) hours of hospitalization. These hypotheses will be tested in adult inpatients who are determined to be at risk for alcohol withdrawal and are subsequently placed on the SEWS monitoring and treatment protocol. These patients will be randomized to baclofen 10mg three times daily vs placebo. Condition or disease Intervention/treatment Phase Alcohol Withdrawal Syndrome Drug: Baclofen Drug: Placebo Phase 3 Detailed Description: See Brief Summary. Patients will recieve standard of Care treatment

2014 Clinical Trials

27. Intrathecal Baclofen Withdrawal: A Rare Cause of High Morbidity and Mortality. (Abstract)

Intrathecal Baclofen Withdrawal: A Rare Cause of High Morbidity and Mortality.

2014 Chest

28. Baclofen overdose mimicking anoxic encephalopathy: a case report and review of the literature Full Text available with Trip Pro

Baclofen overdose mimicking anoxic encephalopathy: a case report and review of the literature A patient who has overdosed on baclofen can present with significant neurological symptoms suggestive of a serious brain insult, but with appropriate diagnosis and treatment they often fully recover within 72 h. If the patient had been maintained on chronic baclofen therapy prior to the overdose, one must be watchful for signs of baclofen withdrawal as recovery from the overdose occurs.

2017 Therapeutic advances in drug safety

29. Double Blind Placebo Control Opipramol-Baclofen Treatment for Addiction

previous studies showed partial efficacy with no significant relapse in relapse rates. The same is true for the use of GABAb-1 receptor antagonist. Opipramol is a selective agonist for sigma-1 receptor. It is clinically used as an antidepressant and anxiolytic agent. Moreover, previous open and controlled trials indicated that the GABAb-1 antagonist baclofen partial efficacy in suppressing withdrawal symptoms in alcohol addicts and cocaine. Our studies in an animal model for addiction have shown (...) . It is clinically used as an antidepressant and anxiolytic agent. Drug: Opipramol PO Drug: Baclofen PO Active Comparator: Drug-B baclofen 90 mg per day (3*30) Baclofen is a GABAb-1 antagonist and has shown partial efficacy in suppressing withdrawal symptoms in alcohol addicts and cocaine. Drug: Opipramol PO Drug: Baclofen PO Outcome Measures Go to Primary Outcome Measures : Decreased craving [ Time Frame: 1 month ] Lower withdrawal symptom will be measured by questionnaires Eligibility Criteria Go

2017 Clinical Trials

30. Baclofen

death, low birth weight, preterm delivery and adverse neurodevelopmental effects. Further research is therefore required. Neonatal withdrawal has been reported following maternal use of oral baclofen. Delivery in a unit with adequate neonatal facilities is therefore advised if maternal use has occurred in the weeks prior to delivery. Due to the lack of safety data the need for additional fetal monitoring needs to be considered on a case-by-case basis. Other risk factors may also be present (...) Baclofen USE OF BACLOFEN IN PREGNANCY 0344 892 0909 USE OF BACLOFEN IN PREGNANCY (Date of issue: January 2019 , Version: 3 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Baclofen is a gamma-aminobutyric acid (GABA) agonist licensed for oral

2014 UK Teratology Information Service

31. Alcohol Withdrawal Protocols for Acute Care Inpatients: Clinical Effectiveness and Guidelines

(at a dose of 10 mg/kg) to a lorazepam-based withdrawal protocol was found to result in fewer admissions to the intensive care unit and did not have an effect on adverse events when compared with the placebo add-on. 1 In inpatients with symptoms of alcohol withdrawal syndrome, patients randomized to baclofen add-on therapy (10 mg, three times a day) were less likely to require high doses (defined as =20 mg over 72 hours) of lorazepam than those receiving the placebo add-on. 2 Four relevant guidelines (...) , Graffman S, Vahidnia F, et al. Phenobarbital for acute alcohol withdrawal: a prospective randomized double-blind placebo-controlled study. J Emerg Med. 2012 Sep 19. PubMed: PM22999778 2. Lyon JE, Khan RA, Gessert CE, Larson PM, Renier CM. Treating alcohol withdrawal with oral baclofen: a randomized, double-blind, placebo-controlled trial. J Hosp Med. 2011 Oct;6(8):469-74. PubMed: PM21990176 Guidelines and Recommendations 3. National Collaborating Centre for Mental Health. Alcohol-use disorders

2013 Canadian Agency for Drugs and Technologies in Health - Rapid Review

32. Preventing Alcohol Withdrawal With Oral Baclofen

Preventing Alcohol Withdrawal With Oral Baclofen Preventing Alcohol Withdrawal With Oral Baclofen - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Preventing Alcohol Withdrawal With Oral Baclofen (BACLOFEN (...) Information provided by (Responsible Party): Jeffrey E Lyon, Essentia Health Study Details Study Description Go to Brief Summary: The purpose of this study is determine if the medication baclofen can prevent the symptoms of Alcohol Withdrawal Syndrome (AWS) in hospitalized patients who may be at risk for AWS. This medication is most often used for patients who have spasticity of their muscles due to a neuromuscular disease. In several European studies, and in an earlier study at Essentia Health

2013 Clinical Trials

33. Phenibut (β-Phenyl-γ-aminobutyric Acid) Dependence and Management of Withdrawal: Emerging Nootropics of Abuse Full Text available with Trip Pro

phenibut and was successfully treated with a baclofen taper. This case report highlights the development of phenibut use disorder with coingestion of alcohol and potential management for phenibut withdrawal. We believe clinicians must be aware of how phenibut dependence may present and how to manage the withdrawal syndrome. (...) Phenibut (β-Phenyl-γ-aminobutyric Acid) Dependence and Management of Withdrawal: Emerging Nootropics of Abuse This case report describes the development of withdrawal from phenibut, a gamma-aminobutyric acid-receptor type B agonist. Although phenibut is not an FDA-approved medication, it is available through online retailers as a nootropic supplement. There are reports of dependence in patients that misuse phenibut. We report a case in which a patient experienced withdrawal symptoms from

2018 Case reports in psychiatry

34. Baclofen Withdrawal Presenting as Irritability in a Developmentally Delayed Child Full Text available with Trip Pro

Baclofen Withdrawal Presenting as Irritability in a Developmentally Delayed Child Irritability in children has a broad differential diagnosis, ranging from benign processes to life-threatening emergencies. In children with comorbid conditions and developmental delay, the diagnostic process becomes more challenging. This case report describes a developmentally delayed 14-year-old boy who presented with pain and crying caused by a malfunction of a surgically implanted baclofen pump. We describe

2012 Western Journal of Emergency Medicine

35. Dissociative intoxication and prolonged withdrawal associated with phenibut: a case report Full Text available with Trip Pro

. Friend Samantha F SF Jimenez Berenice B Steiger Louisa R LR eng R25 MH101072 MH NIMH NIH HHS United States Case Reports Letter United States J Clin Psychopharmacol 8109496 0271-0749 0 GABA Agonists 56-12-2 gamma-Aminobutyric Acid H789N3FKE8 Baclofen T2M58D6LA8 4-amino-3-phenylbutyric acid IM Adult Baclofen therapeutic use Delirium chemically induced drug therapy GABA Agonists adverse effects Humans Male Substance Withdrawal Syndrome drug therapy Substance-Related Disorders drug therapy gamma (...) Dissociative intoxication and prolonged withdrawal associated with phenibut: a case report 28614159 2018 12 17 2018 12 17 1533-712X 37 4 2017 08 Journal of clinical psychopharmacology J Clin Psychopharmacol Dissociative Intoxication and Prolonged Withdrawal Associated With Phenibut: A Case Report. 478-480 10.1097/JCP.0000000000000731 Joshi Yash B YB Department of Psychiatry, University of California, San Diego, La Jolla, CA. yajoshi@ucsd.edu; University of California, San Diego, La Jolla, CA

2017 Journal of Clinical Psychopharmacology

36. Severe Central Sleep Apnea Associated With Chronic Baclofen Therapy: A Case Series. Full Text available with Trip Pro

of baclofen for the treatment of alcohol dependence. We describe severe central sleep apnea (CSA) in four patients with none of the conditions commonly associated with CSA who were receiving chronic baclofen therapy for alcohol withdrawal. In one patient, baclofen withdrawal was associated with a complete resolution of CSA. Three patients were treated by adaptive servo-ventilation while continuing their treatment with baclofen. Given the increasing number of patients receiving baclofen for alcohol (...) withdrawal treatment, physicians should be aware that these patients might be affected by severe CSA. Future studies are required to determine the mechanisms, prevalence, and treatment modalities of sleep-disordered breathing associated with baclofen usage. Copyright © 2016 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

2016 Chest

37. Randomized open-label trial of baclofen for relapse prevention in alcohol dependence. (Abstract)

Randomized open-label trial of baclofen for relapse prevention in alcohol dependence. Alcohol dependence is a progressive chronic disorder characterized by narrowing of the drinking repertoire, salience of drinking, tolerance and withdrawal phenomenon, compulsion to drink, and frequent relapses. Baclofen has been shown to promote abstinence, to reduce craving, and to reduce anxiety in alcohol-dependent individuals, and it promises to be a useful agent, although clinical data are limited (...) at present.The current study aimed to test the utility of baclofen, a GABA agonist, in improving the relapse rates in alcohol-dependent subjects.A total of 122 alcohol-dependent subjects were randomized into two groups. Groups were administered baclofen (30 mg/day) or benfothiamine (a nutritional supplement) using an open label design. Both groups received brief motivational intervention. Subjects were assessed at 0, 2, 4, 8, and 12 weeks for the primary outcome measures: time to first relapse, heavy

2016 The American journal of drug and alcohol abuse Controlled trial quality: uncertain

38. Successful treatment of severe baclofen toxicosis initially refractory to conventional treatment Full Text available with Trip Pro

Successful treatment of severe baclofen toxicosis initially refractory to conventional treatment After ingesting a dose of baclofen thought to be lethal, a patient with severe neurologic signs was successfully managed despite initially being refractory to treatment. Patients with persistent neurologic abnormalities may still have an excellent prognosis despite lack of initial response. Additionally, we present a potential case of benzodiazepine withdrawal.

2016 Clinical Case Reports

39. Intrathecal (IT) Baclofen Drug Distribution

to the lumbar intrathecal space Patients who have an allergic reaction to IT baclofen Patients who have significant headache from CSF withdrawal Patients who have intradural blockage that prevents advancing the IT catheter to the level of C4 Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its (...) Intrathecal (IT) Baclofen Drug Distribution Intrathecal (IT) Baclofen Drug Distribution - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Intrathecal (IT) Baclofen Drug Distribution (ITB) The safety

2016 Clinical Trials

40. Baclofen to Prevent Agitation in Alcohol Addicted Patients in ICU

IPD: No Keywords provided by Nantes University Hospital: alcoholism intensive care Baclofen restlessness Delirium tremens Alcohol withdrawal syndrome Additional relevant MeSH terms: Layout table for MeSH terms Alcoholism Alcohol-Related Disorders Substance-Related Disorders Chemically-Induced Disorders Mental Disorders Ethanol Anti-Infective Agents, Local Anti-Infective Agents Central Nervous System Depressants Physiological Effects of Drugs (...) Baclofen to Prevent Agitation in Alcohol Addicted Patients in ICU Baclofen to Prevent Agitation in Alcohol Addicted Patients in ICU - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Baclofen to Prevent

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>